| Drug / Therapy | Botensilimab, Balstilimab, and SBRT in Colorectal Cancer |
| Indication | — |
| Decision Type | Early Phase 1 |
| Trial Phase | Early Phase 1 |
| ClinicalTrials.gov | NCT07128355 |
Agenus Inc (AGEN) operates in the Immuno-Oncology sector. The current BTS Score is 69 (Grade: B).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Early Phase 1 date for Botensilimab, Balstilimab, and SBRT in Colorectal Cancer by Agenus Inc (AGEN) is scheduled for January 1, 2027. This is the target date for the FDA to make a decision on this application.
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer is being developed by Agenus Inc for the treatment of its target indication. It is currently in Early Phase 1 clinical trials.
If Botensilimab, Balstilimab, and SBRT in Colorectal Cancer receives FDA approval, Agenus Inc (AGEN) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Early Phase 1 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for AGEN on DilutionWatch at dilutionwatch.com/stock/AGEN.html.
You can view the full BiotechSign company profile for Agenus Inc (AGEN) at biotechsign.com/app/company/AGEN, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.